Article Text

PDF
FRI0532 Dual energy x-ray absorptiometry testing in women with breast cancer initiating therapy with aromatase inhibitors reduces subsequent fracture risk
  1. MA Ursani1,
  2. M Suarez-Almazor2,
  3. M Yang2,
  4. H-F Lu2,
  5. H Zhao2,
  6. L Elting2
  1. 1Medicine, Section of Allergy, Immunology and Rheumatology, Baylor College of Medicine
  2. 2Internal Medicine, Rheumatology, The University of Texas M.D. Anderson Cancer Institute, Houston, United States

Abstract

Background Estrogen receptor positive breast cancer is commonly treated with aromatase inhibitors (AI). A well-known adverse effect of this therapy is osteoporosis and related bone fractures. National guidelines have promoted the use of dual energy X-ray absorptiometry (DXA) for screening purposes.

Objectives To evaluate the association between use of DXA among women with breast cancer treated with AI enrolled in Medicare, and subsequent fracture risk.

Methods Retrospective cohort study using the Texas Cancer Registry (TCR) and the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) data linked with Medicare claims. To help estimate the likelihood of performing a DXA, a multivariable logistic regression model was used. Covariates of age, ethnicity, stage, residence area, and socioeconomic variables were controlled for the analyses. The outcome variable a DXA claim within 12 months after the initiation of the AI therapy. Cox regression model to evaluate time to first fracture after initiation of AI.

Results The total number of cases within the SEER-Medicare database was 15,350 and in the TCR 4,532. Women aged between 66–74 years and Non-Hispanic white were more likely to get DXA than were Hispanic and Non-Hispanic Black.

In TCR, 2714 patients did not get treatment for osteoporosis in the first 12 months after AI therapy initiation. 2989 patients did not receive treatment for osteoporosis within 12 months of obtaining their first DXA scan. 1330 patients who did not undergo DXA were not treated for osteoporosis; and 1384 patients who underwent DXA got treated for osteoporosis.

The duration of AI treatment was negatively associated with the risk of fracture. Women who received DXA scan showed 11% lower risk of fracture than those who were not scanned (HR 0.89 (0.83, 0.94).

Conclusions National guidelines suggest to obtain a DXA and start bisphosphonate therapy in female breast cancer patients who are treated with AI therapy. Our data suggests that the majority of women in the TCR and SEER database were not treated for osteoporosis within the first 12 months after initiation of AI therapy. Women who received DXA scan showed a lower risk of fracture than those who were not scanned.

References

  1. National guidelines suggest to obtain a DXA and start bisphosphonate therapy in female breast cancer patients who are treated with AI therapy. Our data suggests that the majority of women in the TCR and SEER database were not treated for osteoporosis within the first 12 months after initiation of AI therapy. Women who received DXA scan showed a lower risk of fracture than those who were not scanned.

References

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.